JP7644002B2 - 多形化合物およびその使用 - Google Patents
多形化合物およびその使用 Download PDFInfo
- Publication number
- JP7644002B2 JP7644002B2 JP2021522528A JP2021522528A JP7644002B2 JP 7644002 B2 JP7644002 B2 JP 7644002B2 JP 2021522528 A JP2021522528 A JP 2021522528A JP 2021522528 A JP2021522528 A JP 2021522528A JP 7644002 B2 JP7644002 B2 JP 7644002B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- present
- patient
- pharma
- peaks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
- C07C225/04—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated
- C07C225/06—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Inorganic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024174435A JP2025000975A (ja) | 2018-10-24 | 2024-10-03 | 多形化合物およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862749922P | 2018-10-24 | 2018-10-24 | |
| US62/749,922 | 2018-10-24 | ||
| PCT/US2019/057815 WO2020086816A1 (en) | 2018-10-24 | 2019-10-24 | Polymorphic compounds and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024174435A Division JP2025000975A (ja) | 2018-10-24 | 2024-10-03 | 多形化合物およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022505849A JP2022505849A (ja) | 2022-01-14 |
| JP2022505849A5 JP2022505849A5 (cg-RX-API-DMAC7.html) | 2022-10-31 |
| JP7644002B2 true JP7644002B2 (ja) | 2025-03-11 |
Family
ID=70328246
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021522528A Active JP7644002B2 (ja) | 2018-10-24 | 2019-10-24 | 多形化合物およびその使用 |
| JP2024174435A Pending JP2025000975A (ja) | 2018-10-24 | 2024-10-03 | 多形化合物およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024174435A Pending JP2025000975A (ja) | 2018-10-24 | 2024-10-03 | 多形化合物およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US11345654B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3870158A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7644002B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN113164414A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2019364542B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3117336A1 (cg-RX-API-DMAC7.html) |
| MX (2) | MX2021004710A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020086816A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX389001B (es) | 2015-10-23 | 2025-03-20 | Navitor Pharm Inc | Moduladores de interacción de sestrina-gator2 y sus usos. |
| ES3040534T3 (en) | 2017-04-26 | 2025-11-03 | Navitor Pharm Inc | Modulator of sestrin-gator2 interaction for use in the treatment of treatment-resistant depression |
| WO2020086816A1 (en) | 2018-10-24 | 2020-04-30 | Navitor Pharmaceuticals, Inc. | Polymorphic compounds and uses thereof |
| AU2020376950B2 (en) | 2019-11-01 | 2026-06-11 | Supernus Pharmaceuticals, Inc. | Methods of treatment using an mTORC1 modulator |
| CN115927459A (zh) * | 2022-07-19 | 2023-04-07 | 华南农业大学 | 猪ctns基因在促进动物骨骼肌生长中的应用 |
| KR20250111125A (ko) * | 2022-11-01 | 2025-07-22 | 나비토르 파마슈티칼스 인코포레이티드 | mTORC1 활성의 조절제 및 이의 용도 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017501113A (ja) | 2013-10-23 | 2017-01-12 | ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ | アミノ酸によるmTORC1の調節およびその使用 |
| WO2017070518A1 (en) | 2015-10-23 | 2017-04-27 | Navitor Pharmaceuticals, Inc. | Modulators of sestrin-gator2 interaction and uses thereof |
| JP2018507910A (ja) | 2015-02-12 | 2018-03-22 | ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ジ・ユニバーシティ・オブ・アリゾナ | 神経芽細胞腫を治療する方法 |
| JP2018065772A (ja) | 2016-10-21 | 2018-04-26 | 国立大学法人山口大学 | mTORC1活性化抑制剤 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4110368A (en) | 1972-07-24 | 1978-08-29 | American Cyanamid Company | Hydro substituted prostanoic acids and esters |
| US4346110A (en) | 1981-06-01 | 1982-08-24 | Merrell Toraude Et Compagnie | Method for treating depression |
| JPS61149964A (ja) | 1984-12-25 | 1986-07-08 | Canon Inc | 電子写真感光体 |
| US4670196A (en) | 1985-09-05 | 1987-06-02 | Norton Company | Tower packing element |
| ES2029799T3 (es) | 1986-01-24 | 1992-10-01 | Toray Industries, Inc. | Derivados de 2,5,6,7 tetranor-4,8-inter-m-fenilen pg12. |
| GB8827885D0 (en) | 1988-11-30 | 1989-01-05 | Wellcome Found | Novel heterocyclic pesticidal compounds |
| US5639600A (en) | 1994-08-05 | 1997-06-17 | The Regents Of The University Of California | Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement |
| DE19623142A1 (de) | 1996-06-10 | 1997-12-11 | Huels Chemische Werke Ag | Enantiomerenangereicherte, durch einen tertiären Kohlenwasserstoffrest substituierte Malonsäuremonoester sowie deren Herstellung |
| HUP9903916A3 (en) | 1996-08-28 | 2001-06-28 | Procter And Gamble Co Cincinna | Phosphinic acid amides and pharmaceutical compositions containing the same |
| US7087648B1 (en) | 1997-10-27 | 2006-08-08 | The Regents Of The University Of California | Methods for modulating macrophage proliferation using polyamine analogs |
| WO1999055688A1 (en) | 1998-04-27 | 1999-11-04 | Warner-Lambert Company | Substituted diarylalkyl amides as calcium channel antagonists |
| BR9907140A (pt) | 1998-11-04 | 2000-10-17 | Montell Technology Company Bv | Componentes catalìticos sólidos, catalisadores e processo para a (co) polimerização de olefinas ch2=chr. |
| US6329546B1 (en) | 1999-01-12 | 2001-12-11 | Laboratory Of Molecular Biophotonics | Caged amino acids |
| US20030203900A1 (en) | 1999-05-18 | 2003-10-30 | Martin Quibell | Cysteine protease inhibitors |
| CZ300834B6 (cs) | 1999-06-10 | 2009-08-19 | Warner-Lambert Company Llc | Mono- a disubstituované kyseliny 3-propyl-gamma-aminomáselné |
| KR100833371B1 (ko) | 2001-04-27 | 2008-05-28 | 젠야쿠코교가부시키가이샤 | 헤테로시클릭 화합물 및 이를 유효 성분으로 하는 항종양제 |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| MXPA05001766A (es) | 2002-08-14 | 2005-08-19 | Atugen Ag | Uso de proteina quinasa n beta. |
| US6787664B2 (en) | 2002-09-17 | 2004-09-07 | Warner-Lambert Company Llc | Process for preparing single enantiomers of 5,5,5,5′,5′,5′-hexafluoroleucine and protected analogs |
| AU2002953255A0 (en) | 2002-12-11 | 2003-01-02 | Cytopia Research Pty Ltd | Protein kinase inhibitors |
| WO2004089925A1 (en) | 2003-04-03 | 2004-10-21 | Semafore Pharmaceuticals, Inc. | Pi-3 kinase inhibitor prodrugs |
| ES2382377T3 (es) | 2003-05-30 | 2012-06-07 | Gemin X Pharmaceuticals Canada Inc. | Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer |
| WO2005007623A2 (en) | 2003-07-03 | 2005-01-27 | The Trustees Of The University Of Pennsylvania | Inhibition of syk kinase expression |
| LT2612862T (lt) | 2004-05-13 | 2017-01-25 | Icos Corporation | Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai |
| US20070212428A1 (en) | 2004-06-04 | 2007-09-13 | Mood Management Sciences, Inc. | Methods and compositions for treating mood disorder |
| US7449458B2 (en) | 2005-01-19 | 2008-11-11 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| MX2007009985A (es) | 2005-02-18 | 2008-03-11 | Innodia Inc | Diastereoisomeros de 4-hidroxiisoleucina y usos de los mismos. |
| ES2493466T3 (es) | 2005-05-12 | 2014-09-11 | Abbvie Bahamas Ltd. | Promotores de la apoptosis |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| HRP20140975T1 (hr) | 2005-10-07 | 2014-11-21 | Exelixis, Inc. | Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze |
| WO2007053452A1 (en) | 2005-11-01 | 2007-05-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| HUE028588T2 (hu) | 2005-12-13 | 2016-12-28 | Incyte Holdings Corp | Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| KR101533461B1 (ko) | 2006-04-26 | 2015-07-02 | 에프. 호프만-라 로슈 아게 | Pi3k저해제로 유용한 티에노[3,2-d]피리미딘 유도체 |
| CN101573334A (zh) | 2006-08-21 | 2009-11-04 | 普雷萨药品公司 | 用于治疗中枢神经系统障碍的多介质转运体抑制剂 |
| EP2529621B1 (en) | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| EP2069339B1 (en) | 2006-09-25 | 2011-05-18 | Wockhardt Research Centre | Substituted piperidinophenyl oxazolidinones |
| TWI397418B (zh) | 2006-10-10 | 2013-06-01 | Otsuka Pharma Co Ltd | 抗憂鬱劑 |
| RU2009118935A (ru) | 2006-10-20 | 2010-11-27 | Мерк энд Ко., Инк. (US) | Земещенные имидазолы в качестве модуляторов подтипа 3 бомбезиновых рецепторов |
| HUE029188T2 (en) | 2007-03-12 | 2017-03-28 | Ym Biosciences Australia Pty | Phenylamino-pyrimidine compounds and their use |
| US8394794B2 (en) | 2007-03-23 | 2013-03-12 | Regents Of The University Of Minnesota | Therapeutic compounds |
| TW200902019A (en) | 2007-04-26 | 2009-01-16 | Ono Pharmaceutical Co | Dicyclic heterocyclic compound |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| US8431608B2 (en) | 2007-08-17 | 2013-04-30 | Icagen Inc. | Heterocycles as potassium channel modulators |
| US8445686B2 (en) | 2007-08-27 | 2013-05-21 | Abbvie Inc. | 4-(4-pyridinyl)-benzamides and their use as rock activity modulators |
| MY165582A (en) | 2008-03-11 | 2018-04-05 | Incyte Holdings Corp | Azetidine and cyclobutane derivatives as jak inhibitors |
| WO2010005726A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
| JP2012530116A (ja) | 2009-06-19 | 2012-11-29 | レツク・フアーマシユーテイカルズ・デー・デー | 脱ハロゲン化なしにハロゲノアルケンを水素化する方法 |
| US20120219596A1 (en) | 2009-07-30 | 2012-08-30 | Wendelin Stark | Injectable formulation for treatment and protection of patients having an inflammatory reaction or an ischemia-reperfusion event |
| CA2786245A1 (en) | 2010-01-29 | 2011-08-04 | Boehringer Ingelheim International Gmbh | Substituted naphthyridines and their use as syk kinase inhibitors |
| JP5744021B2 (ja) | 2010-06-30 | 2015-07-01 | 富士フイルム株式会社 | 新規なニコチンアミド誘導体またはその塩 |
| CN102464701B (zh) | 2010-11-08 | 2015-10-21 | 上海医药工业研究院 | 一类新型化合物、其制备方法及用途 |
| WO2012076063A1 (en) | 2010-12-10 | 2012-06-14 | Rottapharm S.P.A. | Pyridine amide derivatives as ep4 receptor antagonists |
| EP2678037B1 (en) | 2011-02-25 | 2014-12-03 | Lonza Ltd | Branched linker for protein drug conjugates |
| US9321727B2 (en) | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| US8987456B2 (en) | 2011-10-05 | 2015-03-24 | Merck Sharp & Dohme Corp. | 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors |
| WO2013142229A1 (en) | 2012-03-19 | 2013-09-26 | President And Fellows Of Harvard College | Designing novel peptides for inducing fibronectin matrix assembly |
| EP3202397B1 (en) | 2012-08-06 | 2019-09-25 | Pitney Pharmaceuticals Pty Limited | Compounds for the treatment of mtor pathway related diseases |
| US20160002159A1 (en) | 2013-02-13 | 2016-01-07 | Neal ZONDLO | Perfluoro-tert-butyl hydroxyproline |
| WO2014145852A2 (en) | 2013-03-15 | 2014-09-18 | Knopp Biosciences Llc | Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators |
| WO2014201111A1 (en) * | 2013-06-14 | 2014-12-18 | The Brigham And Women's Hospital, Inc. | Treatment of mtor hyperactive related diseases and disorders |
| WO2017083823A1 (en) | 2015-11-13 | 2017-05-18 | Brandeis University | Mtor inhibitors and methods of use thereof |
| US10512656B2 (en) * | 2016-04-21 | 2019-12-24 | Baylor College Of Medicine | Compositions and methods for the treatment of lysosomal storage disorders and disorders characterized by lysosomal dysfunction |
| ES3040534T3 (en) | 2017-04-26 | 2025-11-03 | Navitor Pharm Inc | Modulator of sestrin-gator2 interaction for use in the treatment of treatment-resistant depression |
| US10653652B2 (en) | 2018-02-08 | 2020-05-19 | Ovid Therapeutics Inc. | Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere'S disease, tourette'S syndrome, attention deficit hyperactivity disorder and addiction |
| WO2020086816A1 (en) | 2018-10-24 | 2020-04-30 | Navitor Pharmaceuticals, Inc. | Polymorphic compounds and uses thereof |
| US10926803B2 (en) | 2019-07-17 | 2021-02-23 | GM Global Technology Operations LLC | Four rail front crush structure with load dissemination into eight element support structure |
| AU2020376950B2 (en) | 2019-11-01 | 2026-06-11 | Supernus Pharmaceuticals, Inc. | Methods of treatment using an mTORC1 modulator |
-
2019
- 2019-10-24 WO PCT/US2019/057815 patent/WO2020086816A1/en not_active Ceased
- 2019-10-24 MX MX2021004710A patent/MX2021004710A/es unknown
- 2019-10-24 CN CN201980077762.2A patent/CN113164414A/zh active Pending
- 2019-10-24 JP JP2021522528A patent/JP7644002B2/ja active Active
- 2019-10-24 US US16/662,517 patent/US11345654B2/en active Active
- 2019-10-24 CA CA3117336A patent/CA3117336A1/en active Pending
- 2019-10-24 EP EP19874934.3A patent/EP3870158A4/en active Pending
- 2019-10-24 AU AU2019364542A patent/AU2019364542B2/en active Active
-
2021
- 2021-04-23 MX MX2025010903A patent/MX2025010903A/es unknown
-
2022
- 2022-05-05 US US17/737,478 patent/US11697633B2/en active Active
-
2023
- 2023-05-30 US US18/203,341 patent/US12252456B2/en active Active
-
2024
- 2024-10-03 JP JP2024174435A patent/JP2025000975A/ja active Pending
-
2025
- 2025-02-14 US US19/053,599 patent/US20250188017A1/en active Pending
- 2025-11-28 AU AU2025271494A patent/AU2025271494A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017501113A (ja) | 2013-10-23 | 2017-01-12 | ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ | アミノ酸によるmTORC1の調節およびその使用 |
| JP2018507910A (ja) | 2015-02-12 | 2018-03-22 | ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ジ・ユニバーシティ・オブ・アリゾナ | 神経芽細胞腫を治療する方法 |
| WO2017070518A1 (en) | 2015-10-23 | 2017-04-27 | Navitor Pharmaceuticals, Inc. | Modulators of sestrin-gator2 interaction and uses thereof |
| JP2018065772A (ja) | 2016-10-21 | 2018-04-26 | 国立大学法人山口大学 | mTORC1活性化抑制剤 |
Non-Patent Citations (3)
| Title |
|---|
| BYRN S,PHARMACEUTICAL SOLIDS: A STRATEGIC APPROACH TO REGULATORY CONSIDERATIONS,PHARMACEUTICAL RESEARCH,米国,KLUWER ACADEMIC PUBLISHERS,1995年07月01日,V12 N7,pp.945-954 |
| TERENCE L THRELFALL,ANALYSIS OF ORGANIC POLYMORPHS A REVIEW,ANALYST,1995年10月,VOL.120,pp.2435-2460,http://pubs.rsc.org/en/content/articlepdf/1995/AN/AN9952002435 |
| 大嶋寛,結晶多形・擬多形の析出挙動と制御,PHARM STAGE,2007年,Vol.6, No.10,pp.48-53,http://pubs.rsc.org/en/content/articlepdf/1995/AN/AN9952002435 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20200131114A1 (en) | 2020-04-30 |
| EP3870158A4 (en) | 2022-08-10 |
| JP2025000975A (ja) | 2025-01-07 |
| US11345654B2 (en) | 2022-05-31 |
| US12252456B2 (en) | 2025-03-18 |
| US11697633B2 (en) | 2023-07-11 |
| EP3870158A1 (en) | 2021-09-01 |
| US20240018091A1 (en) | 2024-01-18 |
| CN113164414A (zh) | 2021-07-23 |
| US20220371985A1 (en) | 2022-11-24 |
| AU2019364542B2 (en) | 2025-08-28 |
| CA3117336A1 (en) | 2020-04-30 |
| MX2021004710A (es) | 2021-06-04 |
| WO2020086816A1 (en) | 2020-04-30 |
| US20250188017A1 (en) | 2025-06-12 |
| MX2025010903A (es) | 2025-10-01 |
| AU2019364542A1 (en) | 2021-06-10 |
| AU2025271494A1 (en) | 2026-01-08 |
| JP2022505849A (ja) | 2022-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025000975A (ja) | 多形化合物およびその使用 | |
| EP3596040B1 (en) | Polymorphic salt of 6-chloro-3-amino-2(2-hydroxypropyl)quinoline and uses thereof | |
| EP3920912B1 (en) | Treatment of ciliopathies using inhibitors of glucosylceramide synthase (gcs) | |
| BR112016009488B1 (pt) | piperidil-etil-pirimidina substituída, seus usos, e composição farmacêutica | |
| EP3685838A1 (en) | Compound for treatment or prevention of obesity or diseases related to obesity, and application thereof | |
| JP2016535101A (ja) | 心臓リモデリング及び他の心疾患の治療 | |
| EP4316487A1 (en) | Composition for preventing or treating neurodegenerative disease comprising compound inducing expression of anti-aging gene klotho | |
| US20230137092A1 (en) | Composition and Method for the Treatment and Prevention of Cardiac, Pulmonary, Dermal, and Renal Fibrosis | |
| JP2012533537A (ja) | コルホルシンダロパートを含む骨疾患の予防または治療用組成物 | |
| CA3176384A1 (en) | Method of treating ship1-mediated diseases using pelorol derivatives | |
| JP5849336B2 (ja) | アデニル酸シクラーゼの活性調節剤 | |
| CN117466866B (zh) | Hedgehog信号通路抑制剂 | |
| WO2020249120A9 (zh) | 氨基硫醇类化合物作为脑神经或心脏保护剂的用途 | |
| JP6185650B2 (ja) | 5−ht4受容体アゴニストとしての5−アミノ−キノリン−8−カルボキサミド誘導体 | |
| EP2473038A1 (en) | Compounds for treating disorders or diseases associated with neurokinin 2 receptor activity | |
| WO2024097285A1 (en) | MODULATORS OF mTORC1 ACTIVITY AND USES THEREOF | |
| CN112843041A (zh) | 迷迭香酸或其衍生物作为新型trpc1拮抗剂的药用制备及其应用 | |
| EP4624482A1 (en) | Pyrimidopyrimidinone compound and pharmaceutical composition comprising same | |
| CN116120335A (zh) | 作为Wnt信号通路激动剂的莪术醇衍生物及其制法和应用 | |
| WO2019114501A1 (zh) | α-楝子素衍生物及其制备方法与应用 | |
| US20190040014A1 (en) | Solid Forms of an S-Nitrosoglutathione Reductase Inhibitor | |
| CN108586484A (zh) | 噻吩并噻喃甲酰胺类化合物及其应用 | |
| HK1247126A1 (zh) | 二羧酸的双酰胺衍生物作爲用於刺激组织再生和恢复减退的组织功能的药剂 | |
| HK1177391A (en) | Compounds for treating disorders or diseases associated with neurokinin 2 receptor activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221021 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221021 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231019 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231024 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240119 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240325 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240603 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241003 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20241125 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20241212 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250214 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250227 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7644002 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |